40,294 Zoetis Inc. $ZTS Shares Bought by Rockland Trust Co.

Rockland Trust Co. lifted its stake in shares of Zoetis Inc. (NYSE:ZTS) by 19.8% in the third quarter, HoldingsChannel reports. The fund owned 244,065 shares of the company’s stock after acquiring an additional 40,294 shares during the period. Rockland Trust Co.’s holdings in Zoetis were worth $17,043,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently made changes to their positions in the business. J. Stern & Co. LLP grew its holdings in Zoetis by 12,431.2% during the 4th quarter. J. Stern & Co. LLP now owns 24,069,492 shares of the company’s stock valued at $3,028,423,000 after buying an additional 23,877,416 shares in the last quarter. Flossbach Von Storch SE bought a new position in Zoetis during the second quarter valued at $302,601,000. BlackRock Inc. raised its position in Zoetis by 10.8% during the second quarter. BlackRock Inc. now owns 39,430,181 shares of the company’s stock valued at $2,833,453,000 after purchasing an additional 3,845,869 shares during the period. Ruane Cunniff & Goldfarb L.P. purchased a new position in shares of Zoetis during the 1st quarter worth about $286,660,000. Finally, Van ECK Associates Corp lifted its position in shares of Zoetis by 269.0% during the fourth quarter. Van ECK Associates Corp now owns 2,387,059 shares of the company’s stock worth $300,340,000 after purchasing an additional 1,740,113 shares during the last quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Stock Performance

Shares of Zoetis stock traded up $0.82 during trading hours on Monday, hitting $70.51. 1,318,579 shares of the company were exchanged, compared to its average volume of 5,582,245. The stock has a market capitalization of $29.14 billion, a price-to-earnings ratio of 11.61, a P/E/G ratio of 1.63 and a beta of 0.74. Zoetis Inc. has a 1 year low of $68.77 and a 1 year high of $148.30. The business has a 50-day moving average of $74.39 and a 200-day moving average of $86.22. The company has a current ratio of 3.08, a quick ratio of 1.84 and a debt-to-equity ratio of 2.87.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Thursday, August 6th. The company reported $1.87 EPS for the quarter, beating analysts’ consensus estimates of $1.85 by $0.02. The firm had revenue of $2.47 billion during the quarter, compared to the consensus estimate of $2.50 billion. Zoetis had a net margin of 27.49% and a return on equity of 74.89%. The firm’s revenue was down .2% compared to the same quarter last year. During the same quarter last year, the firm earned $1.76 earnings per share. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. As a group, analysts expect that Zoetis Inc. will post 6.2 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts recently commented on ZTS shares. BNP Paribas Exane reduced their price objective on shares of Zoetis from $146.00 to $110.00 and set an “outperform” rating for the company in a research note on Tuesday, August 11th. UBS Group dropped their target price on shares of Zoetis from $85.00 to $80.00 and set a “neutral” rating on the stock in a research report on Friday, August 7th. Morgan Stanley set a $85.00 target price on shares of Zoetis in a research note on Friday, August 7th. Citigroup lowered their price objective on Zoetis from $112.00 to $96.00 and set a “buy” rating for the company in a research report on Tuesday, August 11th. Finally, Zacks Research downgraded Zoetis from a “hold” rating to a “strong sell” rating in a report on Monday, August 10th. Eight analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, Zoetis has an average rating of “Hold” and a consensus target price of $101.08.

Zoetis Profile

Zoetis Inc is a global animal health company that develops, manufactures and commercializes medicines, vaccines, diagnostics and other products for pets and livestock. Its portfolio is designed to help prevent and treat disease, improve animal health and support veterinary care.

The company serves the companion animal market with products for dogs, cats and other pets, including parasiticides, vaccines, dermatology treatments and pain-management therapies. Zoetis also provides animal health products for cattle, swine, poultry, fish and other livestock, along with diagnostic instruments, tests and services used by veterinarians and producers.

Zoetis was established as an independent public company in 2013 after being separated from Pfizer, which had operated the business as Pfizer Animal Health.